WHY BENLYSTA?

Dr. William Pendergraft, Nephrologist

Paid consultant to GSK at the time of filming.

  • TRANSCRIPT

    DR. PENDERGRAFT: My name is Doctor Will Pendergraft. I’m a practicing nephrologist in Chapel Hill, North Carolina.

    ON-SCREEN TEXT: Dr. William Pendergraft, Nephrologist
    Paid consultant to GSK at the time of filming

    ON-SCREEN TEXT: “Why BENLYSTA?”

    DR. PENDERGRAFT: One of the most common questions I get from my colleagues who are nephrologists is when and where and how can we use BENLYSTA in patients with lupus nephritis?

    DR. PENDERGRAFT: I think what’s nice is we have data from the BLISS lupus nephritis trial, which for me was a very real-world trial that allowed us to use one of two different remission-induction regimens. Either the ALMS protocol with mycophenolate or Euro-lupus protocol using cyclophosphamide. For us as nephrologists, it’s nice to be able to get to pick one of those two regimens and to know that BENLYSTA can be used at the same time.

    ON-SCREEN TEXT: “… two different remission-induction regimens”

    DR. PENDERGRAFT: And, for me, I think what the BLISS lupus nephritis trial showed was that BENLYSTA is really a new member in the toolkit of our armamentarium for remission-induction and maintenance therapy. Clearly, we can’t use it in every patient, but the BLISS lupus nephritis trial incorporated the remission-induction and maintenance periods, which means there is a wide window in which we can use BENLYSTA in both of those periods.

    ON-SCREEN TEXT: “BENLYSTA is a new member in the toolkit”
    “Induction and maintenance”

    DR. PENDERGRAFT: Thank you for watching. Visit the BENLYSTA website for more information.

    ON-SCREEN TEXT:
    BENLYSTA is indicated for patients aged ≥5 with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy and patients aged ≥18 with active lupus nephritis receiving standard therapy. BENLYSTA is not recommended in patients with severe active central nervous system lupus or in combination with other biologics.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION

    Previous anaphylaxis with BENLYSTA.

    WARNINGS AND PRECAUTIONS

    Serious Infections: Serious and sometimes fatal infections have been reported and occurred more frequently with BENLYSTA. Use caution in patients with severe or chronic infections, and consider interrupting therapy in patients with a new infection.

    Progressive Multifocal Leukoencephalopathy (PML): Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported. If PML is confirmed, consider stopping immunosuppressant therapy, including BENLYSTA.

    Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

    ON-SCREEN TEXT:
    BENLYSTA
    (belimumab)
    Intravenous Use 120 mg/vial
    Subcutaneous Use 200 mg/mL

    GSK Logo

    Trademarks are owned by or licensed to the GSK group of companies. | ©2021 GSK or licensor. BELVID210054 November 2021. Produced in USA.

You may also like

BENLYSTA PATIENT STORY

Dr. Alvin Wells, Rheumatologist

WHY BENLYSTA?

Dr. Grace Wright, Rheumatologist

Paid consultants to GSK at the time of filming.